GE Healthcare
As of the edition of 20 October 2026, GE Healthcare runs 48 drugs, 44 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 44 |
| Went quiet | 1 |
| Stopped | 3 |
| Total | 48 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Albumin human | none listed | 0 |
| Iohexol | none listed | 0 |
| Regadenoson anhydrous | Ends 2027 (patent) | 2 |
| Fluciclovine | none listed | 0 |
| Sodium fluoride | none listed | 0 |
| Xenon | none listed | 0 |
| Iobenguane | none listed | 2 |
| Iodixanol | none listed | 0 |
| Perflubutane | none listed | 0 |
| Fluoroestradiol | none listed | 1 |
| Iodine | none listed | 0 |
| Flutemetamol | none listed | 0 |
| Hexaminolevulinate | none listed | 0 |
| Ioflupane | none listed | 2 |
| Diatrizoic acid | none listed | 0 |
| Flurpiridaz | Ends 2029 (exclusivity) | 0 |
| Selenomethionine | none listed | 0 |
| Technetium tc 99m sulfur colloid | none listed | 0 |
| Strontium chloride | none listed | 0 |
| Sodium iodide | none listed | 0 |
| Gadodiamide | none listed | 0 |
| Gallium citrate | none listed | 0 |
| Mangafodipir | none listed | 0 |
| Iodohippurate | none listed | 0 |
| Technetium medronate | none listed | 0 |
A route B row is one company at one target. 19 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where GE Healthcare needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 8 trials led
- Mental health: 7 trials led
- Cancer: 6 trials led